CorFlow to start Clinical Trial with Inselspital

Please login or
register
09.05.2019
Symboldbild Arzt

Swissmedic, and the Swiss ethics committee, Swissethics, approved CorFlow’s First-in-Man clinical trial for heart attack patients. The first hospital to start enrolling patients will be the University Hospital in Bern.

Zug-based startup CorFlow Therapeutics develops a combined diagnostic and therapeutic medical device for improving microvascular obstructions (MVO) after a heart attack. CorFlow completed the preclinical trials at the University Hospital of Zürich. Now, the biotech startup announced its three-phased First-in-Man clinical trial.

The CorFlow First-in-Man Microvascular Obstruction with CoFl System Assessment (MOCA) I study will generate important information on the safety, feasibility of detecting, quantifying and treating of MVO in acute heart attack patients. CorFlow believes the study will provide early signs on how controlled infusion of intra-coronary agents can reduce the amount of MVO. Microvascular obstruction has been proven in several larger clinical trials to be an independent predictor for major adverse cardiac events such as heart failure and death.  

«The MOCA I study is the first study, which combines diagnosis and treatment of MVO in acute heart attack patients», says Esther Gerteis, CorFlow’s VP Medical Affairs. The first hospital to start enrolling patients will be the University Hospital in Bern. Additional sites will start subsequently. The study is funded by CorFlow and through a grant from Innosuisse.

(Press Release)
(Picture: Pixabay)

0Comments

More news about

CorFlow Therapeutics AG

Company profiles on startup.ch

CorFlow Therapeutics AG

rss